A Real-world Study of Selinexor-based Regimens for Treatment of Non-Hodgkin Lymphoma

Launched by RUIJIN HOSPITAL · May 9, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at a treatment called selinexor for patients with Non-Hodgkin lymphoma, which includes specific types like DLBCL (Diffuse Large B-Cell Lymphoma) and T-cell lymphoma. The goal of the study is to see how well this treatment works and how safe it is for people with these types of lymphoma. Right now, the trial is recruiting participants of all ages and genders who have been diagnosed with DLBCL or T-cell lymphoma and have used selinexor in their treatment within the last three months.

To join the study, participants need to be willing to sign a consent form and provide information about their medical history. However, those who have previously received selinexor or have issues with following treatment plans may not be eligible. If you decide to participate, you can expect regular check-ins related to your health and treatment. This study will help researchers gather important data that could improve future treatments for lymphoma.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Know and voluntarily sign the Informed Consent Form (ICF)
• • Clinically confirmed DLBCL, T or NK cell lymphoma
• • Patients with DLBCL or T or NK cell lymphoma who have used selinexor-based therapy in the past 3 months are included
• • Cooperate with clinical diagnosis and treatment management, and provide disease-related past medical history materials
• Exclusion Criteria:
• • Previously received selinexor
• • Poor patient compliance
• • physicians evaluate that patients are not suitable for enrollment